Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

iCMLf Prizes

iCMLf

Education

Virtual Education Program

    Giora Sharf - Can we safely stop TKI therapies? Experience from the STOP trials (2)

    Non-adherence of CML patients

    Results of the global adherence survey of the CML Advocates Network
    Giora Sharf, CML Advocates Network

     

    Issues covered:

    • Results of the global adherence survey of 2546 CML patients from 79 countries
    • Intentional and non-intentional non-adherence levels
    • Differences between countries, type of TKI, administration schedule, age groups, perception of quality of life and side effects
    • Tools to drive adherence and importance of routine

     

    Click on the "Play" button below to hear the slidecast. Be sure to turn on your speakers to hear the audio!

     


    Please share your feedback below, and view the other Virtual Education Program modules.

     

    Facteur de variabilité de la réponse au ITK</li>
                  <li>Les trois grand mécanismes de résistance</li>
                  <li>La réponse au traitement</li>
                  <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

    Has this been helpful? Please provide your comments here: